Part One of a Two-Part Series
An observation can be made about the typical method through which mass pharmaceutical litigation begins. Initially, the plaintiff files a lawsuit and serves the manufacturer with written discovery requests, seeking information pertaining to adverse events, clinical trials, direct-to-consumer marketing, and the like. The manufacturer objects to each and every request and does not provide one document. The manufacturer then delays, and the plaintiff frets and finally a compromise is worked out whereby limited production will be obtained; attached to that production will be a manufacturer-imposed presumption of confidentiality. At the same time, while the manufacturer strives to keep secret the internal documents showing what it knew and when it knew it, it will issue a press release talking about the wonderful medicine, claiming it is being wrongfully sued and saying that it has never had a reason to think the medicine was unsafe.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]